Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
ALDX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Aldeyra Therapeutics, Inc.NASDAQ: ALDX
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $0, compared with $755.55K a year earlier.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 3.24M | +11168.8% |
| FY2021 | 2021-12-31 | 28.77K | — |
Net Receivables vs competitors
How ALDX compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 6, against a peer median of +1.2%.
- Net receivables amounts to 0.0% of total assets for ALDX, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $108.05M USD | +1.2% | -1.1% | 16.7% | |
| Mar 2026 | $22.22M USD | +31.9% | +199.6% | 19.3% | |
| Mar 2026 | $15.05M USD | -41.0% | +12.9% | 5.2% | |
| Mar 2026 | $1.88M USD | -21.6% | — | 4.6% | |
| Mar 2026 | CHF 1.51M CHF | +63.5% | +18.7% | 1.1% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
GNLXGenelux Corporation | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding ALDX) | — | +1.2% | +15.8% | 0.6% | |
Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 229.79M | 144.42M | 142.82M | 54.53M | 70.04M |
| Short-term Investments | 0 | 29.88M | 0 | 46.62M | 0 |
| Net Receivables | 28.77K | 3.24M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.5M | 3.05M | 4.65M | 2.51M | 1.34M |
| Total Current Assets | 232.75M | 181.02M | 147.81M | 104.07M | 71.78M |
| Property, Plant & Equipment (Net) | 384.35K | 268.54K | 516.58K | 266.96K | 275.86K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 267.26K | 0 |
| Total Non-current Assets | 384.35K | 268.54K | 516.58K | 534.22K | 275.86K |
| Total Assets | 233.14M | 181.29M | 148.33M | 104.61M | 72.06M |
| Account Payables | 1.02M | 133.63K | 1.34M | 180.45K | 158.46K |
| Short-term Debt | 229.61K | 911.76K | 15.15M | 31.37K | 15.25M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 6M | 6M |
| Other Current Liabilities | 1.51M | 3.82M | 3.09M | 4.33M | 4.27M |
| Total Current Liabilities | 11.77M | 15.36M | 22.26M | 18.6M | 27.81M |
| Long-term Debt | 15.5M | 14.92M | 0 | 15M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 6M | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 15.63M | 14.92M | 6.27M | 15M | 0 |
| Total Liabilities | 27.4M | 30.28M | 28.53M | 33.6M | 27.81M |
| Common Stock | 58.08K | 58.56K | 59.2K | 59.65K | 60.16K |
| Retained Earnings | (294.69M) | (356.72M) | (394.26M) | (450.11M) | (483.96M) |
| Accumulated OCI | 0 | (103.94K) | 0 | 37.44K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 205.74M | 151.01M | 119.8M | 71M | 44.25M |
| Total Debt | 15.86M | 16.08M | 15.66M | 15.3M | 15.53M |
| Net Debt | (213.93M) | (128.34M) | (127.17M) | (39.22M) | (54.51M) |
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.